Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
NCT ID: NCT01606735
Last Updated: 2014-09-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
172 participants
INTERVENTIONAL
2012-04-30
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery
NCT01048593
The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
NCT02006888
Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery
NCT02547623
Modified Intraocular Lens to Reduce Eye Inflammation After Cataract Surgery in Uveitis Patients
NCT00001311
A Study of TRS01 in Participants With Post-surgical Ocular Inflammation
NCT04222725
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose 1
IBI-10090
dexamethasone
Dose 2
IBI-10090
dexamethasone
Dose 3
IBI-10090
dexamethasone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IBI-10090
dexamethasone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ICON Bioscience Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wendy Murahashi, MD
Role: STUDY_DIRECTOR
Sponsor GmbH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Inland Eye Specialists
Hemet, California, United States
California Eye Professionals
Temecula, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C11-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.